GM Advisory Group LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

GM Advisory Group LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,399 shares of the company’s stock, valued at approximately $243,000.

Other large investors have also recently modified their holdings of the company. Focus Financial Network Inc. ADV bought a new position in shares of Zoetis during the fourth quarter valued at $2,159,000. Price T Rowe Associates Inc. MD raised its stake in shares of Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Axiom Investors LLC DE raised its stake in shares of Zoetis by 36.3% during the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after acquiring an additional 158,459 shares during the last quarter. Global Assets Advisory LLC bought a new position in shares of Zoetis during the first quarter valued at $8,831,000. Finally, Franklin Street Advisors Inc. NC raised its stake in shares of Zoetis by 4.3% during the first quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after acquiring an additional 5,035 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $220.38.

Zoetis Trading Down 0.3 %

NYSE:ZTS opened at $192.73 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $87.94 billion, a price-to-earnings ratio of 37.13, a PEG ratio of 2.98 and a beta of 0.88. The firm has a fifty day simple moving average of $184.70 and a two-hundred day simple moving average of $174.47. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the company posted $1.41 earnings per share. Analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.